<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Recent data suggest that tryptase, a mast cell enzyme, is expressed in neoplastic cells in <z:mpath ids='MPATH_342'>myeloid leukaemias</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>In several of these patients, increased serum tryptase levels are detectable </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIALS AND METHODS: We have determined serum tryptase levels in 914 patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e>, including <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (n = 156), <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, n = 241), <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, n = 317), systemic <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> (SM, n = 81), non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 59) and <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (n = 26) </plain></SENT>
<SENT sid="3" pm="."><plain>Moreover, tryptase was measured in 136 patients with non-neoplastic <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">haematological disorders</z:e>, 102 with non-<z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">haematological disorders</z:e> and 164 healthy subjects </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In healthy subjects, the median serum tryptase was 5.2 ng mL(-1) </plain></SENT>
<SENT sid="5" pm="."><plain>Elevated serum tryptase levels were found to cluster in myeloid <z:hpo ids='HP_0002664'>neoplasm</z:hpo>, whereas almost <z:hpo ids='HP_0000001'>all</z:hpo> patients with lymphoid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> exhibited <z:mpath ids='MPATH_458'>normal</z:mpath> tryptase </plain></SENT>
<SENT sid="6" pm="."><plain>Among myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, elevated tryptase levels (&gt; 15 ng mL(-1)) were recorded in &gt; 90% of patients with SM, 38% with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 34% with <z:mp ids='MP_0005481'>CML</z:mp> and 25% with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The highest tryptase levels, often &gt; 1000 ng mL(-1), were found in advanced SM and core-binding-factor <z:mpath ids='MPATH_336'>leukaemias</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>In most patients with non-neoplastic <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">haematological disorders</z:e> and non-<z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">haematological disorders</z:e> analysed in our study, tryptase levels were <z:mpath ids='MPATH_458'>normal</z:mpath>, the exception being a few patients with <z:e sem="disease" ids="C1261469" disease_type="Disease or Syndrome" abbrv="ESRD">end-stage kidney disease</z:e> and <z:e sem="disease" ids="C0018889" disease_type="Disease or Syndrome" abbrv="">helminth infections</z:e>, in whom a slightly elevated tryptase was found </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: In summary, tryptase is a new diagnostic marker of myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> and a useful test in clinical haematology </plain></SENT>
</text></document>